Combination of an allosteric matrix metalloproteinase-13 alkaline inhibitor with a selective cyclooxygenase-2 inhibitor with the exception of celecoxib and valdecoxib

摘要

"COMBINATION OF A MATRI METALOPROTEINASE-13 ALKINE ALKINE INHIBITOR WITH A SELECTIVE CYCLOOXIGENASE-2 INHIBITOR EXCEPT CELECOXIB AND VALDECOXIB". The invention relates to a combination comprising an allosteric alkaline MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof, with a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, with the exception of celecoxib or valdecoxib. This invention also provides a method of treating a disease reacting to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the combination of the invention comprising an allosteric alkaline MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof, with a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, with the exception of celecoxib or valdecoxib. This invention also provides a pharmaceutical composition comprising a combination of the invention comprising an allosteric allosteric MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof, with a selective COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, with the exception of celecoxib. or valdecoxib, and a pharmaceutically acceptable carrier, diluent or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric alkaline MMP-13 inhibitor, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical formulation comprising a combination of the invention comprising an allosteric alkaline MMP-13 inhibitor or a pharmaceutically acceptable salt thereof with an NSAID or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient. This invention also provides a method of treating a disease reacting to inhibition of MMP-13 and cyclooxygenase 1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the combination of the invention comprising an allosteric alkaline MMP-13 inhibitor. 13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The combinations of the invention may be further combined with other pharmaceutical agents depending on the disease to be treated.